Waters Completes Transformative Acquisition of BD's Biosciences & Diagnostic Solutions Business
WAT sits 19% above its 52-week low of $275.05 on elevated volume (4.5× avg).
Summary
Waters Corporation has successfully closed its acquisition of BD's Biosciences & Diagnostic Solutions business, creating a global leader in life sciences and diagnostics. The transaction involved a significant share issuance and new debt to finance the deal.
Key Events · M&A and Partnerships · WAT
-
Acquisition Consummated
Waters completed the acquisition of BD's Biosciences & Diagnostic Solutions business, a transformative transaction that reshapes the company's strategic focus.
-
Share Issuance & Ownership Structure
Waters issued 38.5 million shares of common stock to former BD shareholders, who now collectively own approximately 39.2% of the combined company on a fully diluted basis.
-
Significant Debt Incurrence
A $4.0 billion term loan was secured by SpinCo (now a Waters subsidiary) to fund a cash distribution to BD, with Waters entering into a Parent Guarantee Agreement for these obligations.
-
Strategic Restructuring
The company established four new divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences, reflecting its expanded focus.
Analysis · WAT · Industrial Applications And Services
This 8-K announces the consummation of Waters Corporation's previously disclosed acquisition of BD's Biosciences & Diagnostic Solutions business, a major strategic move that fundamentally reshapes the company. The transaction, structured as a Reverse Morris Trust, involved Waters issuing 38.5 million shares, resulting in former BD shareholders owning approximately 39.2% of the combined entity. To finance a $4.0 billion cash distribution to BD, Waters' new subsidiary, SpinCo, secured a $4.0 billion term loan, which Waters has guaranteed. This significant debt and equity issuance will alter Waters' capital structure and financial leverage. The successful closing of this complex, transformative deal, which has been extensively discussed in prior filings (e.g., shareholder approval on Jan 27, strategic rationale on Jan 13), marks a pivotal moment for the company, positioning it as a global leader in high-volume testing and expanding into high-growth adjacent markets. The appointment of Dr. Claire M. Fraser to the board, with her expertise in genomics and molecular diagnostics, further supports the strategic direction of the newly combined business.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WAT was trading at $327.81 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $19.5B. The 52-week trading range was $275.05 to $415.11. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.